|

Actinium-225 Prostate-Specific Membrane Antigen 617 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: 225Ac-PSMA-617, Radioligand 225Ac-PSMA-617

Pipeline

Phase 1: 1

Top Sponsors

  • Thomas Hope1

Indications

  • Very High Risk Prostate Carcinoma1
  • Localized Prostate Carcinoma1
  • High Risk Prostate Cancer1
  • Prostate Cancer (Diagnosis)1
  • Prostate Cancer1

San Francisco, California1 trial

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

University of California, San Francisco

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.